Market Research Logo

Histone Lysine N Methyltransferase EHMT2 (Euchromatic Histone Lysine N Methyltransferase 2 or HLA B Associated Transcript 8 or Histone H3 K9 Methyltransferase 3 or Lysine N Methyltransferase 1C or Protein G9a or EHMT2 or EC 2.1.1.43) - Pipeline Review, H1

Histone Lysine N Methyltransferase EHMT2 (Euchromatic Histone Lysine N Methyltransferase 2 or HLA B Associated Transcript 8 or Histone H3 K9 Methyltransferase 3 or Lysine N Methyltransferase 1C or Protein G9a or EHMT2 or EC 2.1.1.43) - Pipeline Review, H1 2018

Summary

Histone Lysine N Methyltransferase EHMT2 (Euchromatic Histone Lysine N Methyltransferase 2 or HLA B Associated Transcript 8 or Histone H3 K9 Methyltransferase 3 or Lysine N Methyltransferase 1C or Protein G9a or EHMT2 or EC 2.1.1.43) - Euchromatic histone-lysine N-methyltransferase 2 (EHMT2) is a histone methyltransferase encoded by the EHMT2 gene. It mediates monomethylation of 'Lys-56' of histone H3 (H3K56me1) in G1 phase, leading to promote interaction between histone H3 and PCNA and regulating DNA replication. It weakly methylates 'Lys-27' of histone H3 (H3K27me). It is required for DNA methylation.

Histone Lysine N Methyltransferase EHMT2 (Euchromatic Histone Lysine N Methyltransferase 2 or HLA B Associated Transcript 8 or Histone H3 K9 Methyltransferase 3 or Lysine N Methyltransferase 1C or Protein G9a or EHMT2 or EC 2.1.1.43) pipeline Target constitutes close to 6 molecules. Out of which approximately 2 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Preclinical and Discovery stages are 1 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 4 molecules, respectively. Report covers products from therapy areas Oncology, Infectious Disease, Gastrointestinal and Hematological Disorders which include indications Malaria, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Colon Cancer, Hepatocellular Carcinoma, Leukemias, Liver Fibrosis, Lymphoma and Sickle Cell Disease.

The latest report Histone Lysine N Methyltransferase EHMT2 - Pipeline Review, H1 2018, outlays comprehensive information on the Histone Lysine N Methyltransferase EHMT2 (Euchromatic Histone Lysine N Methyltransferase 2 or HLA B Associated Transcript 8 or Histone H3 K9 Methyltransferase 3 or Lysine N Methyltransferase 1C or Protein G9a or EHMT2 or EC 2.1.1.43) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Histone Lysine N Methyltransferase EHMT2 (Euchromatic Histone Lysine N Methyltransferase 2 or HLA B Associated Transcript 8 or Histone H3 K9 Methyltransferase 3 or Lysine N Methyltransferase 1C or Protein G9a or EHMT2 or EC 2.1.1.43) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Histone Lysine N Methyltransferase EHMT2 (Euchromatic Histone Lysine N Methyltransferase 2 or HLA B Associated Transcript 8 or Histone H3 K9 Methyltransferase 3 or Lysine N Methyltransferase 1C or Protein G9a or EHMT2 or EC 2.1.1.43)
  • The report reviews Histone Lysine N Methyltransferase EHMT2 (Euchromatic Histone Lysine N Methyltransferase 2 or HLA B Associated Transcript 8 or Histone H3 K9 Methyltransferase 3 or Lysine N Methyltransferase 1C or Protein G9a or EHMT2 or EC 2.1.1.43) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Histone Lysine N Methyltransferase EHMT2 (Euchromatic Histone Lysine N Methyltransferase 2 or HLA B Associated Transcript 8 or Histone H3 K9 Methyltransferase 3 or Lysine N Methyltransferase 1C or Protein G9a or EHMT2 or EC 2.1.1.43) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Histone Lysine N Methyltransferase EHMT2 (Euchromatic Histone Lysine N Methyltransferase 2 or HLA B Associated Transcript 8 or Histone H3 K9 Methyltransferase 3 or Lysine N Methyltransferase 1C or Protein G9a or EHMT2 or EC 2.1.1.43) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Histone Lysine N Methyltransferase EHMT2 (Euchromatic Histone Lysine N Methyltransferase 2 or HLA B Associated Transcript 8 or Histone H3 K9 Methyltransferase 3 or Lysine N Methyltransferase 1C or Protein G9a or EHMT2 or EC 2.1.1.43) targeted therapeutics
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Histone Lysine N Methyltransferase EHMT2 (Euchromatic Histone Lysine N Methyltransferase 2 or HLA B Associated Transcript 8 or Histone H3 K9 Methyltransferase 3 or Lysine N Methyltransferase 1C or Protein G9a or EHMT2 or EC 2.1.1.43)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Histone Lysine N Methyltransferase EHMT2 (Euchromatic Histone Lysine N Methyltransferase 2 or HLA B Associated Transcript 8 or Histone H3 K9 Methyltransferase 3 or Lysine N Methyltransferase 1C or Protein G9a or EHMT2 or EC 2.1.1.43) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Introduction
Global Markets Direct Report Coverage
Histone Lysine N Methyltransferase EHMT2 (Euchromatic Histone Lysine N Methyltransferase 2 or HLA B Associated Transcript 8 or Histone H3 K9 Methyltransferase 3 or Lysine N Methyltransferase 1C or Protein G9a or EHMT2 or EC 2.1.1.43) - Overview
Histone Lysine N Methyltransferase EHMT2 (Euchromatic Histone Lysine N Methyltransferase 2 or HLA B Associated Transcript 8 or Histone H3 K9 Methyltransferase 3 or Lysine N Methyltransferase 1C or Protein G9a or EHMT2 or EC 2.1.1.43) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Histone Lysine N Methyltransferase EHMT2 (Euchromatic Histone Lysine N Methyltransferase 2 or HLA B Associated Transcript 8 or Histone H3 K9 Methyltransferase 3 or Lysine N Methyltransferase 1C or Protein G9a or EHMT2 or EC 2.1.1.43) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Histone Lysine N Methyltransferase EHMT2 (Euchromatic Histone Lysine N Methyltransferase 2 or HLA B Associated Transcript 8 or Histone H3 K9 Methyltransferase 3 or Lysine N Methyltransferase 1C or Protein G9a or EHMT2 or EC 2.1.1.43) - Companies Involved in Therapeutics Development
Domainex Ltd
Epizyme Inc
Histone Lysine N Methyltransferase EHMT2 (Euchromatic Histone Lysine N Methyltransferase 2 or HLA B Associated Transcript 8 or Histone H3 K9 Methyltransferase 3 or Lysine N Methyltransferase 1C or Protein G9a or EHMT2 or EC 2.1.1.43) - Drug Profiles
BIX-01294 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CM-272 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EZM-8266 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit G9a Protein for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TM-2115 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
verticillin A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Histone Lysine N Methyltransferase EHMT2 (Euchromatic Histone Lysine N Methyltransferase 2 or HLA B Associated Transcript 8 or Histone H3 K9 Methyltransferase 3 or Lysine N Methyltransferase 1C or Protein G9a or EHMT2 or EC 2.1.1.43) - Dormant Products
Histone Lysine N Methyltransferase EHMT2 (Euchromatic Histone Lysine N Methyltransferase 2 or HLA B Associated Transcript 8 or Histone H3 K9 Methyltransferase 3 or Lysine N Methyltransferase 1C or Protein G9a or EHMT2 or EC 2.1.1.43) - Product Development Milestones
Featured News & Press Releases
Dec 11, 2017: Epizyme Presents Preclinical Data on Novel G9a Program and Introduces Next Drug Development Candidate at the American Society of Hematology Annual Meeting
Oct 24, 2012: New Opportunity For Rapid Treatment Of Malaria
Sep 27, 2012: Malaria Takes a Hit-Two New Molecules Stop P. falciparum In Its Tracks
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indication, H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Domainex Ltd, H1 2018
Pipeline by Epizyme Inc, H1 2018
Dormant Projects, H1 2018
List of Figures
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Molecule Type, H1 2018

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report